CHICAGO – As one of the 10 largest medical exhibitions in the U.S., the 2014 AACC Annual Meeting & Clinical Lab Expo is the place where breakthrough innovations in clinical testing and patient care are introduced to the healthcare world. This year, many of the trailblazing products displayed by the Expo’s 650 exhibitors will include the latest diagnostic technology in the field of mobile health.
Advances in smartphones and biosensors have enabled the development of “labs-on-a-chip” that can be brought to the patient, instead of the patient being brought to the lab. This technology is creating a paradigm shift in healthcare delivery that will make it much easier for patients to undergo clinical testing and get the treatment they need, and could be especially beneficial for patients in resource limited or remote settings who don’t have access to a hospital.
New mobile diagnostic and lab-on-a-chip technology found at AACC’s meeting will include:
• A smartphone-based HRDR-200 Rapid Diagnostic Reader by Holomic. This handheld, mobile tool can serve as a portable “smartphone lab” for the diagnosis of thyroid disorders, infectious diseases, and other common health conditions.
• A biochip platform by OJ-Bio, which uses surface acoustic wave (SAW) technology and a hand-held reader connected to a smartphone to test for multiple biomarkers (biological molecules whose presence indicates a condition or disease) simultaneously. These biochips are currently being developed to diagnose HIV, respiratory disease, and periodontal disease.
• A portable, one-step molecular diagnostic system by Coyote Bioscience, which is designed to bring complex genetic testing directly to the patient. On Tuesday, July 29, 1:30–1:50 p.m., Coyote will introduce this point-of-care platform as part of the AACC annual meeting’s OEM Lecture Series.
AACC’s Annual Meeting & Clinical Lab Expo will also feature the newest tests in reproductive health, infectious diseases, drug testing, and much more. One highlight from among these products is Roche’s pioneering cobas HPV Test, the first human papillomavirus (HPV) DNA test approved by the Food and Drug Administration for primary cervical cancer screening. For decades, cervical cytology has been the mainstay of cervical cancer screening, but recent studies have found that HPV screening appears to offer 60–70% greater protection against invasive cervical cancer than cytology. This new HPV test could be integral to preventing cervical cancer in women by enabling cancer precursor cells to be removed before they become malignant.
“This year has seen the emergence of amazing new diagnostic products that promise to change not only clinical testing but the entire model on which the modern healthcare system is based,” said AACC CEO Janet B. Kreizman. “The new technology being featured at the 2014 AACC Annual Meeting & Clinical Lab Expo is the future of laboratory medicine and exemplifies how important diagnostic tests are to enhancing patient health around the globe.”
________________________________________AACC Clinical Lab Expo InformationAACC annual meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc074/media/landing.asp
The McCormick Place exhibit hall will be open during the following hours:
Tuesday, July 29, 9:30 a.m.–5 p.m.
Wednesday, July 30, 9:30 a.m.–5 p.m.
Thursday, July 31, 9:30 a.m.–2 p.m.
About the 2014 AACC Annual Meeting & Clinical Lab ExpoAACC's annual meeting offers 5 days packed with opportunities to learn about exciting science from July 27–31. Plenary sessions feature expert presentations on how mobile technology and the internet are revolutionizing healthcare, the importance of newborn screening, big data, the biologic basis of obesity, and the latest advances that could lead to a cure for HIV.
At the AACC Clinical Lab Expo, more than 650 exhibitors will fill the show floor of Chicago’s convention center, McCormick Place, with displays of the latest diagnostic technology, including but not limited to automation, information systems, point-of-care, and biotech.
About AACCDedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.